Drug Profile
Research programme: interleukin-3 monoclonal antibody - Baxalta
Alternative Names: SM 401Latest Information Update: 06 Mar 2015
Price :
$50
*
At a glance
- Originator SuppreMol; University of Regensburg
- Developer Baxalta
- Class Monoclonal antibodies
- Mechanism of Action Interleukin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 04 Mar 2015 SuppreMol has been acquired by Baxter International
- 07 Mar 2014 No development reported - Preclinical for Rheumatoid arthritis in Germany (parenteral)
- 24 Jul 2012 Preclinical trials in Rheumatoid arthritis in Germany (parenteral)